Medication info

Aminosin Injection

Prescription medicationInjections
Ingredient · strength
L-Leucine›402mg / 100mLL-Isoleucine›330mg / 100mLL-Lysine Hydrochloride›319mg / 100mLL-Valine›319mg / 100mLL-Phenylalanine›308mg / 100mLL-Histidine›264mg / 100mLL-Threonine›231mg / 100mLL-Methionine›220mg / 100mLL-Tryptophan›99mg / 100mLL-Alanine›1138mg / 100mLL-Arginine›632mg / 100mLGlycine›566mg / 100mLL-Proline›374mg / 100mLL-Serine›275mg / 100mLL-Tyrosine›22mg / 100mL
Manufacturer / importer
Daehan Pharmaceutical Co., Ltd.
Appearance
A colorless or pale yellow transparent liquid in a colorless and transparent glass vial injection.
Packaging
200 milliliters/vial, 250 milliliters/vial
Approval status
Active

MFDS item code 202200748 · Approved 2022.02.17

Summary

Main use
Prevention of amino acid deficiency when oral or gastrointestinal nutritional support cannot be provided, is insufficient, or is contraindicated
Who uses it
Adults · Children
Adult dosage
The intravenous dose depends on the patient's clinical condition and requirements for amino acids, electrolytes, and fluids (nutritional status and/or the degree of nitrogen catabolism due to disease). ○ Daily dose: For adults, the reference dose is 0.8g of amino acids per kg of body weight per day (equivalent to 15mL of this drug). Administer at least 180kcal of nonprotein energy source per 1g of nitrogen. Adjust the dose and infusion rate as appropriate according to the patient's age, weight, and clinical condition. Administration Administer by intravenous infusion into a central vein. This drug should be administered with glucose or another source sufficient to provide adequate calories for parenteral nutrition.
Children's dosage
For infants, the daily dose is 2.2g of amino acids per kg of body weight (equivalent to 40mL of this drug)

Ingredients

Manufacturer
Daehan Pharmaceutical Co., Ltd.

Efficacy & effects

Prevention of amino acid deficiency when oral or gastrointestinal nutritional support cannot be provided, is insufficient, or is contraindicated

View approved original text

This medicine is used to provide the necessary amino acids for patients who have difficulty or are unable to receive nutrition orally or through the gastrointestinal tract. It helps improve the nutritional status and assist in protein synthesis in the body. Its primary role is to complement the patient's nutritional imbalance and support recovery.

Dosage and Administration

Adult dosage

The intravenous dose depends on the patient's clinical condition and requirements for amino acids, electrolytes, and fluids (nutritional status and/or the degree of nitrogen catabolism due to disease). ○ Daily dose: For adults, the reference dose is 0.8g of amino acids per kg of body weight per day (equivalent to 15mL of this drug). Administer at least 180kcal of nonprotein energy source per 1g of nitrogen. Adjust the dose and infusion rate as appropriate according to the patient's age, weight, and clinical condition. Administration Administer by intravenous infusion into a central vein. This drug should be administered with glucose or another source sufficient to provide adequate calories for parenteral nutrition.

Children's dosage

For infants, the daily dose is 2.2g of amino acids per kg of body weight (equivalent to 40mL of this drug)

Precautions

This medication must be used under medical supervision. Patients with allergies to the ingredients of this medication or those with progressive liver disease, at risk of hepatic coma should not use this medication. Patients with severe renal dysfunction or hypernitrogenemia, congenital amino acid metabolism disorders, and patients with metabolic acidosis should also not receive this medication. Patients with heart failure or acute pulmonary failure, conditions that require excessive fluid supply, patients with oliguria or anuria, and patients who have had a myocardial infarction should avoid this medication. Patients with dehydration should adequately supply fluids and electrolytes to correct their status before cautious administration. Patients with hyponatremia or hypokalemia should ensure sufficient sodium and potassium supply and exercise caution. Patients with impaired liver or kidney function should adjust the dosage according to their condition and carefully monitor liver function and blood ammonia levels. Patients with pulmonary edema or heart failure should be administered while closely monitoring fluid status. For patients with congenital non-protein amino acid metabolism disorders and infants under 2 years old, the benefits and risks should be carefully evaluated before administration. This medication may cause anaphylaxis or hypersensitivity reactions in the immune system, and adverse hematologic reactions have also been reported. Metabolic complications such as nitrogenemia, hyperammonemia, liver dysfunction, cholestasis, and hepatic steatosis may occur during non-oral nutritional therapy. Inflammation, pain, erythema, etc., may occur at the infusion site, so care is required. Excessive addition of calcium and phosphates may pose a risk of forming calcium phosphate precipitates, so solutions and infusion sets should be regularly inspected. Frequent measurement of blood ammonia levels is necessary, and if hyperammonemia occurs, administration should be halted and the condition assessed. Serum electrolyte concentrations, blood sugar, fluid balance, acid-base balance, and kidney and liver functions should be regularly checked. This medication is important to administer alongside appropriate sources of energy, vitamins, trace elements, and electrolytes as part of non-oral nutrition. For adequate protein synthesis, it is mandatory to administer it along with a non-protein energy source such as concentrated glucose solution. When combined with glucose solution, hyperglycemia, diabetes, and hyperosmolar syndrome may occur, so blood and urine sugar levels should be monitored. With high-volume administration, attention must be given to electrolyte balance, and when using with other nutritional solutions, the possibility of peripheral venous administration should be determined based on osmotic concentration. Hyperosmolar solutions may irritate peripheral veins, so caution is required. Mixtures containing amino acids may promote acute folate deficiency, so folate should be administered daily. The safety of this medication has not been sufficiently studied in pregnant or breastfeeding women, and it should only be used when the therapeutic benefits outweigh the risks. The safety and efficacy in children have not been adequately established. The elderly may have reduced body functions, so the rate of administration should be slow and dosage adjusted. Overdosage or excessive infusion rates may lead to blood volume overload, electrolyte imbalance, acidosis, and nitrogenemia; in such cases, administration must be stopped immediately. This medication is sensitive to light, so it should be shielded when administered to children under 2 years old, and after mixing, it should be prepared under sterile conditions and used immediately. If the solution is discolored or cloudy, or if the packaging is damaged, it should not be used and should be stored at room temperature away from direct sunlight.

Side effects

  • Anaphylaxis
  • anaphylactic reactions
  • hypersensitivity reactions
  • fever
  • chills
  • hypotension
  • hypertension
  • arthralgia
  • myalgia
  • urticaria
Show 23 more
  • rash
  • pruritus
  • erythema
  • headache
  • pulmonary vascular deposition
  • nitrogenemia
  • hyperammonemia
  • liver failure
  • cirrhosis
  • liver fibrosis
  • cholestasis
  • hepatic steatosis
  • increased blood bilirubin
  • increased liver enzymes
  • cholecystitis
  • cholelithiasis
  • thrombophlebitis
  • phlebitis
  • pain
  • erythema
  • heat sensation
  • swelling
  • induration

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect from air exposure, and it is best to keep it in a cool place at a temperature between 1 degree and 25 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

A colorless or pale yellow transparent liquid in a colorless and transparent glass vial injection.

Package unit

200 milliliters/vial, 250 milliliters/vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.